Galectin Therapeutics Q1 net loss $9.6M; Belapectin shows liver stiffness reduction at EASL

GALECTIN THERAPEUTICS INC

2025-Q1 EPS reported -$0.15

Net loss for Q1 2025 was $9.6M ($0.15 per share) vs $11.5M ($0.19) in Q1 2024.
Cash and equivalents $7.4M as of March 31, 2025; additional $11M available under lines of credit; runway through August 2025.
Belapectin 2 mg/kg showed statistically significant reduction in liver stiffness from baseline at weeks 26, 52, 78 (p<0.02).
Proportion of patients with >30% worsening in liver stiffness: 11.7% for belapectin vs 23.9% for placebo (51% fewer, p=0.03).
Data presented at EASL May 2025; Fast Track Designation for belapectin in MASH cirrhosis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.